Voxelotor and albuminuria in adults with sickle cell anaemia
暂无分享,去创建一个
[1] Andrew Srisuwananukorn,et al. Effects of renin‐angiotensin blockade and APOL1 on kidney function in sickle cell disease , 2021, EJHaem.
[2] A. Raj,et al. Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study. , 2020, Blood advances.
[3] K. Ataga,et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. , 2019, The New England journal of medicine.
[4] I. Aban,et al. Severe anemia early in life as a risk factor for sickle-cell kidney disease. , 2017, Blood.
[5] R. Hebbel,et al. Sickle cell disease: renal manifestations and mechanisms , 2015, Nature Reviews Nephrology.
[6] M. Gladwin,et al. Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia , 2014, British journal of haematology.
[7] Tamir Kanias,et al. Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease. , 2012, The Journal of clinical investigation.
[8] P. Nawroth,et al. Urinary L‐FABP and anaemia: distinct roles of urinary markers in type 2 diabetes , 2010, European journal of clinical investigation.
[9] C. Ince,et al. Acute decrease in renal microvascular PO2 during acute normovolemic hemodilution. , 2007, American journal of physiology. Renal physiology.